Articles related to NON-HODGKIN LYMPHOMA (NHL)
Newly Defined High-Risk MCL Subgroup Has “Dismal” Outcomes
The recent study on MCL reveals a promising approach in identifying high-risk patients through the combination of MIPI-c and p53 overexpression. This method may guide the development of targeted therapies and personalized treatment plans, addressing the unmet needs of those at the highest risk.
Hematology/Oncology August 21st 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
The phase 3 trial findings underscore the potential of axi-cel as a robust second-line treatment for early relapsed or refractory large B-cell lymphoma, providing promising strides in improving patient survival rates.
Hematology/Oncology July 25th 2023
Epkinly Approved for Relapsed, Refractory Diffuse Large B-Cell Lymphoma
Explore how the recent FDA approval of Epkinly is poised to transform the therapeutic landscape for adults with relapsed or refractory DLBCL and high-grade B-cell lymphoma.
Hematology/Oncology June 27th 2023
Key Points From the SHINE Trial in Mantle Cell Lymphoma
Judith Trotman, MBChB, FRACP, FRCPA, clinical professor at the University of Sydney in Concord, New South Wales, Australia, and head of the Hematology Department at Concord Repatriation General Hospital, provides background on mantle cell lymphoma, its unique treatment challenges, and the significance of the SHINE trial, which assessed ibrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma.
Hematology November 14th 2022
CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL): A Comprehensive Review
CAR T-cell therapy has changed the treatment paradigm for relapsed/refractory aggressive B-cell NHL. The approach has seen strong response rates and durable remission in those whose disease has progressed despite multiple prior treatments. This review outlines current indications for CAR T-cell therapy, major toxicities, novel CARs under investigation, CARs for various hematologic malignancies, and future directions.
Hematology/Oncology May 25th 2022
Moderna COVID-19 Vaccine May Be More Effective in CLL Patients
In a single-center study of 240 patients with lymphoid malignancies — 181 with CLL, 21 with WM, and 38 with other non-Hodgkin lymphomas (NHLs) – patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine compared to the Pfizer-BioNTech vaccine. This superior response was demonstrated in both treatment naïve and treated CLL populations in the study.
Hematology/Oncology April 12th 2022